Short Interest in Vifor Pharma AG (OTCMKTS:GNHAF) Decreases By 22.2%

Vifor Pharma AG (OTCMKTS:GNHAFGet Rating) saw a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 700 shares, a decline of 22.2% from the April 15th total of 900 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

GNHAF stock opened at $173.25 on Monday. The company has a 50-day simple moving average of $174.55 and a 200 day simple moving average of $158.20. Vifor Pharma has a fifty-two week low of $112.75 and a fifty-two week high of $183.50.

Vifor Pharma Company Profile (Get Rating)

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.

Further Reading

Receive News & Ratings for Vifor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vifor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.